

20 February 2012

Proposal to fund prasugrel

PHARMAC is seeking feedback on a proposal to fund prasugrel hydrochloride (Effient) through a provisional agreement with Eli Lilly.

In summary, this proposal would result in prasugrel hydrochloride (Effient) being fully funded from 1 April 2012 for clopidogrel-allergic patients who have undergone coronary angioplasty or had a cardiac stent inserted.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Monday, 5 March 2012** to:

Sue Anne Yee
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: sueanne.yee@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

- Prasugrel hydrochloride (Effient) 5 mg and 10 mg tablets would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 April 2012 as follows:

Chemical	Presentation	Brand	Pack size	Price and subsidy
Prasugrel hydrochloride	tab 5 mg	Effient	28	\$108.00
Prasugrel hydrochloride	tab 10 mg	Effient	28	\$120.00

- Prasugrel hydrochloride would be funded subject to the following Special Authority restriction:

Initial application - (coronary angioplasty) from any relevant practitioner. Approvals valid for 3 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*

Initial application - (bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*

Initial application - (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*

Renewal - (coronary angioplasty) from any relevant practitioner. Approvals valid for 3 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*

Renewal - (bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*

Renewal - (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*

Note: *Clopidogrel allergy is defined as a history of anaphylaxis, urticaria or asthma in non-asthmatic patients within four hours of ingesting clopidogrel.

Background

Prasugrel hydrochloride (Effient) is an antiplatelet agent indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention (PCI).

Prasugrel hydrochloride has been reviewed by PTAC and its Cardiovascular Subcommittee on a number of occasions. PTAC recommended that it be funded with:

- low priority for patients undergoing PCI who are clopidogrel-allergic; and
- low priority for patients who developed stent thrombosis whilst on clopidogrel.

The proposal relating to prasugrel hydrochloride in patients who developed stent thrombosis whilst on clopidogrel cannot be progressed at this time due to relatively low cost-effectiveness when compared to PHARMAC's other options for funding at this time. Details on the other subgroups of patients, for whom prasugrel has been considered for funding, can be found on PHARMAC's website at:

<http://www.pharmac.govt.nz/patients/DecisionMakingProcess/ApplicationTracker>.